NEW YORK, April 22 - Celera Genomics has appointed Kathy Ordoñez president, the company said today. Applera, Celera's parent, said Ordoñez will pull double duty as president of Celera Diagnostics. [For an updated version of this story, click here.]
Separately today, Applera said Applied Biosystems will now exclusively market and distribute Celera's Discovery System and integrate the CDS platform "and other genomic and biological information" into a new "knowledge business." [For an updated verion of this story, click here.]
ABI said this new business will include "genomic assays and related content, as well as other information-rich products, services, and analytical tools to meet the needs of its life sciences customers" and will be marketed on an "expanded information portal."
Terms of the intra-corporate transaction call for Celera to give ABI exclusive marketing and distribution rights to the CDS, as well as access to its content, in exchange for a royalty stream on revenues to be generated by the new knowledge business. Celera will continue to earn revenue from current CDS customers, it said.
The move was made to "free Celera's executive team to focus on therapeutic discovery and development with the same access to this genomic and biological information it has presently while maximizing the return to Celera from its CDS product," Applera said.
Applera plans to announce and detail the moves in a conference call at 10:00 Eastern time today.
Ordoñez, who will continue to answer to Tony White, chief of Applera, was named predient of Celera Diagnostics, the firm's first, in December 2000. She comes to Celera Genomics via Celera Diagnostics and a life-science tour of duty that included several senior executive positions with Hoffmann La-Roche, including a nine-year run as president and CEO of Roche Molecular Systems.
"Kathy has a proven track record in leading successful organizations and translating new complex scientific concepts and technologies into viable, market leading businesses of significant value," White said in a statement. "Our evaluation of her business and managerial experience, compared to a wide range of external candidates, led to the conclusion that Kathy Ordoñez is the best leader for both of these businesses."
White added: "While her leadership is expected to facilitate scientific cooperation between Celera Genomics and Celera Diagnostics, her appointment does not signal any change to the corporate structure, or a combination of these businesses."